Kadima Hi-Tech

Kadimastem is an Israeli clinical-stage biotechnology company specializing in the development of regenerative medicine therapies derived from human embryonic stem cells (hESCs). The company's proprietary technology platform enables the large-scale production of high-quality human cells, including neural cells and insulin-producing pancreatic cells, to treat chronic and debilitating diseases. Its lead product candidate, AstroRx, is an astrocyte cell therapy that has completed a Phase 1/2a clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS), demonstrating a positive safety profile and signals of efficacy. Kadimastem is currently preparing for Phase 2 clinical trials in the United States following FDA clearance of its Investigational New Drug (IND) application. Additionally, the company is advancing IsletRx, a cell therapy aimed at providing a functional cure for patients with insulin-dependent diabetes by replacing damaged pancreatic islet cells.